News & Updates
Showing Multidisciplinary articles
Showing

Early ivermectin use does not confer benefit for COVID-19
In outpatients with an early diagnosis of COVID-19 at high risk for serious illness, treatment with the antiparasitic ivermectin did not reduce the incidence of hospital admission due to disease progression or of prolonged emergency department observation, findings from the TOGETHER trial suggest.

Elacestrant ups PFS vs SoC ET in ER-positive, HER2-negative advanced breast cancer
Elacestrant, a novel oral selective oestrogen receptor (ER) degrader, significantly improves progression-free survival (PFS) vs standard-of-care (SoC) endocrine therapy (ET) in patients with ER-positive, HER2-negative advanced breast cancer whose disease progressed after 1–2 prior lines of ET and a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, results of the phase III EMERALD trial have shown.

NAFLD tied to CVD risk even in lean patients
Individuals with nonalcoholic fatty liver disease (NAFLD) – despite having a lean body or healthy BMI – are at an elevated risk for peripheral vascular disease, stroke, and cardiovascular disease (CVD), a finding that surprises gastroenterologists and researchers at DDW 2022.





